ORUM (475830) - Total Assets
Based on the latest financial reports, ORUM (475830) holds total assets worth ₩191.52 Billion KRW (≈ $129.79 Million USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 475830 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
ORUM - Total Assets Trend (2022–2024)
This chart illustrates how ORUM's total assets have evolved over time, based on quarterly financial data. Check ORUM cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
ORUM - Asset Composition Analysis
Current Asset Composition (December 2024)
ORUM's total assets of ₩191.52 Billion consist of 79.6% current assets and 20.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩19.70 Billion | 0.0% |
| Accounts Receivable | ₩2.44 Billion | 1.6% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩30.61 Billion | 19.9% |
| Intangible Assets | ₩0.00 | 0.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how ORUM's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ORUM stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ORUM's current assets represent 79.6% of total assets in 2024, an increase from 59.5% in 2022.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, the same as 0.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is property, plant & equipment at 19.9% of total assets.
ORUM Competitors by Total Assets
Key competitors of ORUM based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
ORUM - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 28.33 | 22.03 | 22.03 |
| Quick Ratio | 28.33 | 22.03 | 22.03 |
| Cash Ratio | 1.31 | 5.21 | 5.21 |
| Working Capital | ₩155.02 Billion | ₩121.18 Billion | ₩121.18 Billion |
ORUM - Advanced Valuation Insights
This section examines the relationship between ORUM's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -4.9% |
| Total Assets | ₩153.84 Billion |
| Market Capitalization | $424.14K USD |
Valuation Analysis
Below Book Valuation: The market values ORUM's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: ORUM's assets decreased by 4.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for ORUM (2022–2024)
The table below shows the annual total assets of ORUM from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩153.84 Billion ≈ $104.25 Million |
-4.91% |
| 2023-12-31 | ₩161.78 Billion ≈ $109.64 Million |
+660.16% |
| 2022-12-31 | ₩21.28 Billion ≈ $14.42 Million |
-- |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, wh… Read more